NCT07452432Recruiting
Korean Prospective Upper Tract Urothelial Carcinoma Cohort
Prospective Establishment of a Recurrence Monitoring Cohort in Korean Patients With Upper Tract Urothelial Carcinoma
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial carcinoma (UTUC). Eligible adult patients scheduled to receive neoadjuvant chemotherapy followed by radical nephroureterectomy will undergo circulating tumor DNA (ctDNA) sampling prior to chemotherapy initiation and once between 1-6 months after surgery. Clinical, imaging, pathological, and longitudinal follow-up data will be prospectively collected to enable long-term monitoring of recurrence and survival outcomes. The primary objective is to establish a prospective cohort integrating clinical and molecular data to support future translational research and recurrence prediction modeling in UTUC.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 28 Feb 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Jan 2030
- Lead sponsor
- Samsung Medical Center
- Diseases
- Bladder cancer
- NCT number
- NCT07452432
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jan 2026 to the primary completion date, 1 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Evidence of distant metastasis (M1)
- Contraindication to cisplatin-based chemotherapy
- Uncontrolled infection or severe comorbid medical condition
- Pregnancy or breastfeeding
- Any condition that, in the investigator's judgment, makes participation inappropriate
Who the study is looking for
- Age ≥ 19 years
- Histologically confirmed high-grade upper tract urothelial carcinoma (renal pelvis and/or ureter)
- Clinical stage cT2-T4, cN0-1, M0
- Planned neoadjuvant chemotherapy followed by radical nephroureterectomy
- ECOG performance status 0-1
- Adequate hematologic, hepatic, and renal function
- Ability to provide written informed consent
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.